WCD 2023 Highlights Podcast

In this episode (14:30), Medicom’s correspondent covers 6 presentations from the annual meeting of the the 25th World Congress of Dermatology 2023 (WCD 2023), held in Singapore, from 3–8 July, 2023.
The topics discussed are:

1. Encouraging results for first oral IL-23 receptor antagonist in plaque psoriasis
   A first-in-class, investigational, oral, IL-23 receptor antagonist peptide, provisionally named JNJ-77242113, was associated with improved efficacy outcomes compared with placebo in patients with moderate-to-severe plaque psoriasis, in the phase 2b FRONTIER 1 trial.
2. Novel PPARγ modulator reduces acne manifestations
   The novel PPARγ modulator NAC-GED 5% is associated with improved acne manifestations in patients with moderate-to-severe acne, results of a phase 2b study demonstrated. With an accompanying favourable safety profile, this result provides support for the evaluation of NAC-GED 5% in a phase 3 trial.
3. Promising results for paroxetine in rosacea
   Paroxetine appeared to be an efficacious and safe therapy for patients suffering from moderate-to-severe erythema of rosacea in a first randomised-controlled trial. Further studies looking at the long-term efficacy and in-depth mechanisms of this agent are ongoing.
4. OLYMPIA 2: Excellent results for nemolizumab in prurigo nodularis
   Nemolizumab improved signs and symptoms in patients with moderate-to-severe prurigo nodularis (PN), compared with placebo. Findings from the phase 3 OLYMPIA 2 trial also displayed that the frequency of treatment-emergent adverse events was similar in both study groups.
5. Rocatinlimab delivers efficacy and safety in atopic dermatitis
   Rocatinlimab was associated with significantly improved SCORAD and DLQI scores in patients with moderate-to-severe atopic dermatitis , and these improvements appeared to be maintained during a 20-week off-treatment period, results of a phase 2b trial indicated.
6. Subcutaneous spesolimab for GPP flare prevention
   High-dose, subcutaneous spesolimab was associated with fewer flares over the course of 48 weeks in patients with generalised pustular psoriasis (GPP) compared with placebo. Together with the favourable safety profile of the agent, these results support a role for spesolimab in the prevention of flares in patients with GPP.

Enjoy listening!

Copyright ©2023 Medicom Medical Publishers



Posted on 30 July, 202331 July, 2023